Julie R. Park, MD
Dr. Park is program director for Seattle Children's Hematology/Oncology Education. She specializes in caring for children with neurblastoma and non-Hodgkin's lymphoma.Patient Care Philosophy:
Dr. Park's philosophy is to provide excellent clinical care for her patients and their families in an academic setting focused on improving the treatment of childhood cancer.
Title
- Pediatric Hematology Oncology Specialist, Seattle Children's
- Associate in Clinical Research, Fred Hutchinson Cancer Research Center
- Associate Professor, Department of Pediatrics, Hematology and Oncology Division, University of Washington School of Medicine
Clinical Expertise
Pediatric malignancies, Neuroblastoma, Pediatric Non-Hodgkin's lymphoma
Education And Training
- University of Vermont, MD, 1988
- Residency: University of Washington, 1989-1991
- Fellowship: Fred Hutchinson Cancer Research Center, 1991-1994, and University of Washington, Pediatric Hemtology/ Oncology Fellowship
More Information
For more information about Dr. Julie Park's clinical and research expertise, click here.
Clinical Trials
Dr. Park is the SCCA lead investigator for the following clinical trials:
- Melphalan and Buthionine Sulfoximine Followed by Bone Marrow Transplant for Children With Resistant or Recurrent Neuroblastoma (NANT 9902)
- Fenretinide LXS for Recurrent, Refractory, or Persistent Neuroblastoma (NANT 2004-04)
- Intravenous Fenretinide for Young Patients With Recurrent or Resistant Neuroblastoma (NANT 2004-03)
- Cyclophosphamide and Prednisone w/wo Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma (COG ANBL00P3)
- Isotretinoin w/wo Monoclonal Antibody, Interleukin-2, and Sargramostim post STM (COG ANBL0032)
- Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia (COG ADVL0413)
